Insulet Corporation

Insulet Corporation

About Insulet Corporation

Simplify's Rating
Why Insulet Corporation is rated
B+
Rated A on Competitive Edge
Rated A on Growth Potential
Rated C on Rating Differentiation

Industries

Biotechnology

Healthcare

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

Acton, Massachusetts

Founded

2000

Overview

Simplify Jobs

Simplify's Take

What believers are saying

  • Insulet won $452 million in a trade secrets trial against EOFlow.
  • Omnipod 5 expansion in Europe increases market reach and potential revenue.
  • New Malaysian facility supports production scale-up and job creation.

What critics are saying

  • Regulatory challenges may hinder Omnipod 5's European market expansion.
  • Legal battles from the EOFlow case could affect Insulet's financial stability.
  • Geopolitical risks in Malaysia may impact the new facility's operations.

What makes Insulet Corporation unique

  • Insulet's Omnipod 5 integrates with Dexcom G7 CGM, enhancing diabetes management.
  • Insulet is a leader in tubeless insulin pump technology with its Omnipod brand.
  • Omnipod 5's iPhone app availability boosts accessibility for U.S. users.

Help us improve and share your feedback! Did you find this helpful?

Funding

Total Funding

$134.6M

Below

Industry Average

Funded Over

6 Rounds

Post IPO Equity funding comparison data is currently unavailable. We're working to provide this information soon!
Post IPO Equity Funding Comparison
Coming Soon

Benefits

Remote Work Options

Growth & Insights and Company News

Headcount

6 month growth

-1%

1 year growth

-1%

2 year growth

-1%
Financial Modeling Prep
Mar 6th, 2025
Ubiquiti Inc. (NYSE:UI) Outshines Peers in Capital Efficiency

Ubiquiti competes with companies like Fair Isaac Corporation, Paylocity Holding Corporation, Monolithic Power Systems, EPAM Systems, and Insulet Corporation.

MPO Magazine
Jan 14th, 2025
Insulet Rolls Out Omnipod 5 in Five More European Countries

Also in June 2024, Insulet launched Omnipod 5 with the Dexcom G7 CGM.

Bloomberg Law
Dec 5th, 2024
Insulet Wins $452 Million in Insulin Pump Trade Secrets Trial

EOFlow Co. Ltd. must pay Insulet Corp. $452 million for stealing trade secrets related to its insulin pumps, a Massachusetts federal jury ruled.

MPO Magazine
Dec 5th, 2024
Insulet Wins $452 Million Trade Secret Victory Against EOFlow

Insulet was awarded $170 million in compensatory damages from EOFlow and a further $282 million in exemplary damages for willful and malicious misappropriation.

Stock Titan
Oct 29th, 2024
Omnipod(R) 5 App for iPhone(R) Now Fully Available in the United States

ACTON, Mass.-(BUSINESS WIRE)- Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod(R) brand of products, today announced the full market release of the Omnipod 5 App for iPhone(R) in the U.S.

Recently Posted Jobs

Sign up to get curated job recommendations

Insulet Corporation is Hiring for 123 Jobs on Simplify!

Find jobs on Simplify and start your career today

💡
We update Insulet Corporation's jobs every few hours, so check again soon! Browse all jobs →